ArticleThe Journal of clinical endocrinology and metabolism2009
Bioactive insulin-like growth factor-I in obesity.
Article in The Journal of clinical endocrinology and metabolism, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Exploring the Therapeutic Potential of Targeting GH and IGF-1 in the Management of Obesity: Insights from the Interplay between These Hormones and Metabolism.International journal of molecular sciences · 2023Pooled it
- Trends in insulin-like growth factor-1 levels after bariatric surgery: a systematic review and meta-analysis.International journal of obesity (2005) · 2022Pooled it
- Growth Hormone Administration Improves Nonalcoholic Fatty Liver Disease in Overweight/Obesity: A Randomized Trial.The Journal of clinical endocrinology and metabolism · 2023Trial
- The effect of growth hormone on bioactive IGF in overweight/obese women.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2018Trial
- Effects of short-term treatment with orlistat on growth hormone/insulin-like growth factor-I axis in obese post-menopausal women.Journal of endocrinological investigation · 2011Trial
- Sclerostin deficiency sensitizes white adipocytes to thermogenic signals that induce beiging in mice.Nature communications · 2026Article
- Influence of Lifestyle on Brain Sensitivity to Circulating Insulin-like Growth Factor 1.International journal of molecular sciences · 2025Article
- Association Between Visceral Fat and Lung Function Impairment in Overweight and Grade I Obese Women: A Cross-Sectional Study.Advances in respiratory medicine · 2024Article
- Growth hormone/insulin-like growth factor I axis in health and disease states: an update on the role of intra-portal insulin.Frontiers in endocrinology · 2024Review
- Metabolic surgery-induced changes of the growth hormone system relate to improved adipose tissue function.International journal of obesity (2005) · 2023Article
- Causal factors underlying diabetes risk informed by Mendelian randomisation analysis: evidence, opportunities and challenges.Diabetologia · 2023Review
- β Cell mass expansion during puberty involves serotonin signaling and determines glucose homeostasis in adulthood.JCI insight · 2022Article
- The GH/IGF-1 Axis Is Associated With Intrahepatic Lipid Content and Hepatocellular Damage in Overweight/Obesity.The Journal of clinical endocrinology and metabolism · 2022Article
- Growth Hormone and Insulin-Like Growth Factor 1 Regulation of Nonalcoholic Fatty Liver Disease.The Journal of clinical endocrinology and metabolism · 2022 · on this mapReview
- Gestational Diabetes Mellitus and Energy-Dense Diet: What Is the Role of the Insulin/IGF Axis?Frontiers in endocrinology · 2022Review
- Profiling of Insulin-Like Growth Factor Binding Proteins (IGFBPs) in Obesity and Their Association With Ox-LDL and Hs-CRP in Adolescents.Frontiers in endocrinology · 2021Article
- Altered GH-IGF-1 Axis in Severe Obese Subjects is Reversed after Bariatric Surgery-Induced Weight Loss and Related with Low-Grade Chronic Inflammation.Journal of clinical medicine · 2020Article
- Article
- Body mass index predicts cognitive aging trajectories selectively for females: Evidence from the Victoria Longitudinal Study.Neuropsychology · 2020Article
- Anthropometric and biochemical correlates of PAPP-A2, free IGF-I, and IGFBP-3 in childhood.European journal of endocrinology · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
contextIn obesity, total IGF-I is not reduced to the degree predicted by low GH levels, and free IGF-I levels are normal to high. Total and free IGF-I may not reflect IGF-I biological activity because immunoassays cannot account for the modifying effects of IGF binding proteins on interactions between IGF-I and its receptor.
objectiveThe aim of the study was to investigate the biological activity of IGF-I in obesity. DESIGN AND
settingWe conducted a cross-sectional study at a General Clinical Research Center. STUDY
participantsThirty-four healthy women (11 lean, 12 overweight, and 11 obese) of comparable age (overall mean, 30.7 +/- 1.3 yr) participated in the study.
interventionThere were no interventions.
main outcome measuresWe measured bioactive IGF-I (as measured by a kinase receptor activation assay), IGFBP-1, and GH using 6-h pools of serum collected every 10 min for 24 h, and fasting IGF-I and IGFBP-3.
resultsMean 24-h GH (R = -0.76; P < 0.0001), total IGF-I (R = -0.36; P = 0.040), and IGFBP-1 (R = -0.41; P = 0.017) levels were inversely associated with BMI, whereas bioactive IGF-I and IGFBP-3 levels were not. Mean bioactive IGF-I was similar in the groups [2.72 +/- 0.22 (lean), 3.10 +/- 0.32 (overweight), and 2.43 +/- 0.23 [corrected] (obese) microg/liter; overall P = 0.22]. Percentage bioactive IGF-I [(bioactive/total IGF-I) x 100] was higher in obese subjects than both lean and overweight subjects (P = 0.039).
conclusionsDespite low GH secretion in obesity and decreasing IGFBP-1 with increasing BMI, 24-h mean bioactive IGF-I levels are not reduced in obese women and do not correlate with BMI or IGFBP-1 levels. This argues against elevated bioactive IGF-I as the etiology of reduced GH secretion through a feedback mechanism in obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.